Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Sequential Preoperative Fluorodeoxyglucose-positron Emission Tomography Assessment Of Response To Preoperative Chemoradiation: A Means For Determining Longterm Outcomes Of Rectal Cancer.

J. Guillem, H. Moore, T. Akhurst, D. Klimstra, L. Ruo, M. Mazumdar, B. Minsky, L. Saltz, W. Wong, S. Larson
Published 2004 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
BACKGROUND We have previously demonstrated that fluorodeoxyglucose-positron emission tomography (FDG-PET) can assess extent of pathologic response of primary rectal cancer to preoperative chemoradiation. Our goal was to determine the prognostic significance of FDG-PET assessment of rectal cancer response to preoperative chemoradiation. STUDY DESIGN Fifteen patients with locally advanced primary rectal cancer (clinically bulky or tethered, or ultrasound evidence of T3-4 disease, N1 disease, or both) deemed eligible for preoperative radiation and 5-FU-based chemotherapy (5,040 cGy to the pelvis and 2 cycles of bolus 5-FU/leucovorin) were prospectively enrolled from May 1997 to September 1998. FDG-PET was performed before and 4 to 5 weeks after completion of preoperative chemoradiation. FDG-PET parameters included maximum standard uptake value (SUV(max)), total lesion glycolysis (TLG), and visual response score. Patients were prospectively followed after operation, and disease status was determined. RESULTS All patients demonstrated some degree of response to preoperative therapy based on pathologic examination. At a median followup of 42 months (range 23 to 54 months), 11 patients had no evidence of disease and 4 had died of disease. The mean percentage decrease in SUV(max) (DeltaSUV(max)) was 69% for patients free from recurrence and 37% for patients with recurrence (p = 0.004). DeltaSUV(max) >or= 62.5 and deltaTLG >or= 69.5 were the best predictors of no-evidence-of-disease status and freedom from recurrence. Patients with DeltaSUV(max) >or= 62.5 and deltaTLG >or= 69.5 had significantly improved disease-specific and recurrence-free survival (p = 0.08, 0.02 and p = 0.03, 0.01, respectively). CONCLUSIONS Our results indicate that FDG-PET assessment of locally-advanced rectal cancer response to preoperative chemoradiation may predict longterm outcomes.
This paper references
10.1093/ANNONC/MDF081
Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer.
P. Flamen (2002)
10.1038/sj.bjc.6600122
Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [18F]FDG PET
C. Bokemeyer (2002)
10.2307/2532836
RESAMPLING PROCEDURES TO COMPARE TWO SURVIVAL DISTRIBUTIONS IN THE PRESENCE OF RIGHT-CENSORED DATA
G. Heller (1996)
10.1200/JCO.2000.18.8.1689
Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Primary Chemotherapy in Breast Cancer
M. Schelling (2000)
10.1097/00000658-200207000-00012
Long-Term Prognostic Significance of Extent of Rectal Cancer Response to Preoperative Radiation and Chemotherapy
L. Ruo (2002)
10.1016/S0959-8049(99)00229-4
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.
H. Young (1999)
Adjuvant therapy in rectal cancer.
Cohen Am (1992)
Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer.
V. Rusch (1995)
10.1200/JCO.2001.19.2.414
Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
K. Spaepen (2001)
10.1007/BF02055370
Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer
A. Grann (1997)
10.1200/JCO.2002.07.132
Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114.
J. Tepper (2002)
10.1200/JCO.1995.13.6.1417
Tumor proliferation in rectal cancer following preoperative irradiation.
C. Willett (1995)
10.1111/J.1365-2168.1997.02796.X
Long‐term results of preoperative radiation therapy alone for stage T3 and T4 rectal cancer
N. Ahmad (1997)
10.1007/s10350-004-6545-x
A Pathologic Complete Response to Preoperative Chemoradiation Is Associated With Lower Local Recurrence and Improved Survival in Rectal Cancer Patients Treated by Mesorectal Excision
J. García-Aguilar (2003)
10.1200/JCO.1996.14.1.156
Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma.
B. Bates (1996)
Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET.
D. N. Jones (1996)
PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
L. Kostakoglu (2002)
10.1054/bjoc.2000.1166
FDG–PET in the prediction of survival of patients with cancer of the pancreas: a pilot study
N. Maisey (2000)
10.1002/hed.10037
FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma
E. Brun (2002)
10.1177/030089160208800611
Paclitaxel and Carboplatin in Neo-Adjuvant and Concomitant Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
G. Fornari (2002)
10.1056/NEJM199707173370304
Chemoradiotherapy Followed by Surgery Compared with Surgery Alone in Squamous-Cell Cancer of the Esophagus
J. Bosset (1997)
10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C
Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations
A. Mandard (1994)
10.1016/S1095-0397(99)00016-3
Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis.
S. Larson (1999)
10.1200/JCO.2000.18.8.1676
Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy.
I. C. Smith (2000)
10.1200/JCO.2001.19.12.3058
Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging.
W. Weber (2001)
10.1097/00000658-200103000-00002
Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma: Response Evaluation by Positron Emission Tomography
B. Brücher (2001)
10.1007/BF02237238
Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography
J. Guillem (2000)



This paper is referenced by
10.1016/J.IJROBP.2006.02.031
18F-FDG-PET for evaluation of the response to concurrent chemoradiation therapy with intensity-modulated radiation technique for Stage T4 nasopharyngeal carcinoma.
T. Yen (2006)
10.1097/MNM.0000000000000120
Are PREDIST criteria better than PERCIST criteria as a PET predictor of preoperative treatment response in rectal cancer?
A. Maffione (2014)
10.1016/j.ijrobp.2008.07.050
Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation.
A. Konski (2009)
10.1016/S1359-6349(05)80298-8
Radiotherapy in rectal cancer: technical aspects and regimens
V. Valentini (2005)
10.1245/s10434-014-3753-z
Systematic Review of FDG-PET Prediction of Complete Pathological Response and Survival in Rectal Cancer
Sameer Memon Fracs (2014)
10.1097/RLU.0000000000000319
Quantitative PET factors predictive of the response to therapy in solid tumors: which is the best?
A. Maffione (2014)
10.1088/0031-9155/53/22/019
Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres.
P. Flamen (2008)
10.1016/j.soc.2010.06.003
Optimal follow-up to curative colon and rectal cancer surgery: how and for how long?
T. Asgeirsson (2010)
10.2147/CEG.S4778
Recent advances in the management of carcinoma of the rectum
S. Basu (2009)
10.1007/s11864-016-0403-7
Optimal Imaging Strategies for Rectal Cancer Staging and Ongoing Management
S. Balyasnikova (2016)
10.1053/J.SEMNUCLMED.2005.12.002
Gastrointestinal tract malignancies and positron emission tomography: an overview.
F. Esteves (2006)
10.2214/AJR.05.0902
Long-term prognostic value of 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy.
C. Capirci (2006)
10.1158/1078-0432.CCR-11-2139
18F-FDG-PET/CT Imaging as an Early Survival Predictor in Patients with Primary High-Grade Soft Tissue Sarcomas Undergoing Neoadjuvant Therapy
K. Herrmann (2012)
10.1007/978-1-61779-062-1_6
FDG PET and PET/CT for colorectal cancer.
D. Delbeke (2011)
10.4251/wjgo.v2.i5.213
Positron emission tomography as predictor of rectal cancer response during or following neoadjuvant chemoradiation.
S. Hopkins (2010)
10.1038/ncpgasthep1366
Proteomic and metabolic prediction of response to therapy in gastrointestinal cancers
K. Herrmann (2009)
10.1117/12.630711
Decline in NAD(P)H autofluorescence precedes apoptotic cell death from chemotherapy
S. Toms (2005)
10.1016/j.ijrobp.2010.10.029
Repeated positron emission tomography-computed tomography and perfusion-computed tomography imaging in rectal cancer: fluorodeoxyglucose uptake corresponds with tumor perfusion.
M. Janssen (2012)
10.1245/s10434-012-2773-9
What is the Incidence of Metastatic Lymph Node Involvement After Significant Pathologic Response of Primary Tumor Following Neoadjuvant Treatment for Locally Advanced Rectal Cancer?
H. Tranchart (2012)
10.1016/S1470-2045(07)70202-4
Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer.
B. O'Neill (2007)
10.1016/j.ijrobp.2010.11.038
PET-based treatment response evaluation in rectal cancer: prediction and validation.
M. Janssen (2012)
[Roles of F-18 FDG PET or PET/CT for the evaluation of gastrointestinal malignancies].
M. Yun (2006)
10.1007/s00066-006-1504-1
High-Precision Radiation Therapy with Integrated Biological Imaging and Tumor Monitoring
A. Grosu (2006)
10.1016/B978-1-4377-2232-1.00017-6
Chapter 17 – Colorectal Cancer
Cher Heng Tan (2012)
Feasibility and performance of novel software to quantify metabolically active volumes and 3D partial volume corrected SUV and metabolic volumetric products of spinal bone marrow metastases on 18F-FDG-PET/CT.
D. Torigian (2011)
10.1016/j.radonc.2010.09.021
(18)F-FDG PET bio-metabolic monitoring of neoadjuvant therapy effects in rectal cancer: focus on nodal disease characteristics.
F. Calvo (2010)
10.1007/978-1-4020-9804-8_5
Selection of Patients for Resection of Hepatic Colorectal Metastases: 18F-Fluorodeoxyglucose/Positron Emission Tomography
R. Auer (2009)
Multi-modality imaging for treatment response evaluation in rectal cancer
Marco H.M. Janssen (2011)
10.1097/MNM.0b013e3283495662
Clinical utility of 18F-FDG PET parameters in patients with advanced nasopharyngeal carcinoma: predictive role for different survival endpoints and impact on prognostic stratification
S. Chan (2011)
10.1007/s00268-009-0248-3
Accuracy of MRI and 18F-FDG PET/CT for Restaging After Preoperative Concurrent Chemoradiotherapy for Rectal Cancer
Y. Cho (2009)
Firmas Génicas de respuesta al tratamiento neoadyuvante en el cáncer de recto
R. Muíño (2014)
10.1016/j.ejro.2017.06.002
Assessment of stereotactic radiosurgery treatment response for brain metastases using MRI based diffusion index
Zengai Chen (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar